Fidel Salazar Bravo, APRN
Nurse Practitioner · Miami, FLNPI 1649832643
Payments from drug & device makers
Across 50 payments — averaging $34.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$281
- AstraZeneca$254
- Lilly USA, LLC$208
- Daiichi Sankyo Inc.$110
- Merck$105
- Seagen Inc.$95
- plus $647 from 16 others
What the payments were for
- Food & beverage$1,21371%
- Education$48829%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 3 | $281 |
| AstraZeneca | 6 | $254 |
| Lilly USA, LLC | 6 | $208 |
| Daiichi Sankyo Inc. | 4 | $110 |
| Merck | 5 | $105 |
| Seagen Inc. | 1 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Tersera Therapeutics LLC | 3 | $68 |
| Sanofi | 1 | $68 |
| Array Biopharma Inc | 2 | $59 |
| Novartis | 2 | $58 |
| Johnson & Johnson | 2 | $45 |
| Genentech USA, Inc. | 2 | $40 |
| Gilead | 1 | $34 |
| Puma Biotechnology, Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $34 |
| Immunogen, Inc. | 1 | $31 |
| Springworks Therapeutics, Inc. | 1 | $24 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Novocure Inc. | 1 | $18 |
| Beone Medicines USA, Inc. | 1 | $17 |
| Amgen | 1 | $14 |
How this compares
$1,701 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 24 | $13,555 |
| Ondansetron Hcl | 32 | $434 |
| Prochlorperazine Maleate | 16 | $170 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $148 |
| Dexamethasone | 18 | $131 |
| Hydrocortisone | 11 | $130 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Miami
- Margarita FernandezMiami$311K
- Maya BloombergMiami$202K
- Haydee KapinMiami$97K
- Terri PollackMiami$59K
- Amber FederizoMiami$39K
- Patricia Novoa-VogtMiami$35K
- Moriane JosephMiami$23K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.